Entering text into the input field will update the search result below

U.S. IPO Week Ahead: 1 Biotech Expected In The Week Ahead, 4 Deals Could Launch Starting Monday

Mar. 03, 2018 7:16 AM ETZS, DBX, BTAI, BWB, TLC, RCUS, PYPD

Only one small biotech is on the calendar for the week ahead as the annual mid-February lull has been drawn out slightly longer than expected. That said, four deals are able to launch on Monday, and another three become eligible the week after, including high-profile deals Zscaler (ZS) (eligible Monday, March 5) and Dropbox (DBX) (eligible Monday, March 12).

U.S. IPO Calendar


Deal Size
Market Cap

Price Range
Shares Filed


BioXcel Therapeutics (BTAI)
Branford, CT


$11 - $13


Developing new uses of drugs to treat neurological disorders and cancer.

BioXcel Therapeutics, which is being spun out of its R&D-focused parent, is expected to raise $60 million in the upcoming week. Lead candidate, BXCL501, is a sublingual thin film formulation for acute treatment of agitation resulting from Alzheimer's disease, schizophrenia and bipolar disease; management plans to initiate a Phase 1b safety study in 2018.

IPO Pipeline Update

Beginning Monday, March 5, cyber security unicorn Zscaler, Minnesota-based bank Bridgewater Bancshares (BWB) and biotechs Taiwan Liposome Co. (TLC) and Arcus Biosciences (RCUS) will become eligible to launch their deals, along with PolyPid (POLY), which is able to launch now. In the following week, decacorn cloud storage provider Dropbox, customer services provider IBEX Holdings (IBEX) and Chinese online course provider Sunlands Online Education (STG) will be able to set terms.

8 Recent Filings Could Launch in the Coming Weeks


Deal Size






Goldman Sachs

Developing extended-release drugs to prevent surgical site infections.




Morgan Stanley

Provides a cloud-based network security service for enterprises.

Taiwan Liposome Co.



Cantor Fitz.

Developing lipid formulations of approved drugs for pain and eye disease.

Bridgewater Bancshares



Sandler O'Neill

Minnesota bank with six branches and $1.6 billion in assets.

This article was written by

Renaissance Capital provides pre-IPO research to institutional investors and investment banks. The Firm manages two IPO-focused funds: The Renaissance IPO ETF (NYSE: IPO) and the Renaissance International IPO ETF (NYSE: IPOS). Individual investors can get a free overview of the IPO market on www.renaissancecapital.com, and try a free trial of our premium platform, IPO Pro (ipopro.renaissancecapital.com). Through Renaissance Capital’s pre-IPO research service, institutional investors get an independent opinion, in-depth fundamental analysis, and customizable financial models on all IPOs.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.